Given the refinement of HER2-low interpretation guidelines in breast cancer, we hope that standardized criteria more suitable for the expression characteristics of gynecologic tumors, particularly for HER2-low interpretation, will be established soon. This evidence concerns the gene ERBB2 and breast carcinoma.